Gregorio Spagni

M.D., Ph.D. | Neurologist // Autoimmune Neurology.
Consultant Neurologist | Lecturer @ UniFI / AOU Careggi; previously Postdoc @ AG Prüss, Charité, Berlin

[Andreu Vilaseca @andreuvilaseca7]

Big step forward for #MOGAD treatment!🚨
Our multicenter @JAMANeuro study shows that IL-6 receptor blockade (90% in Tocilizumab) markedly reduces relapses, achieving relapse-free outcomes comparable to high-dose IVIG (≥1g/kg/month).
If satralizumab gains approval for MOGAD, these data support #Tocilizumab as a widely available, lower-cost option thanks to biosimilars!
A great example of collaboration across the Americas🌎
#Neurology #MOG #NeuroTwitter

[Valentina Damato @damato_v]

Our systematic review on seronegative MG is now published in Muscle & Nerve. Across 31 studies (712 patients), nearly 1/4 of patients were treatment refractory, emphasizing the need for improved diagnostics and more effective therapeutic strategies.https://t.co/GH9fACmNEU

[Valentina Damato @damato_v]

💚🩵 June is Myasthenia Gravis Awareness Month

Yesterday, the David in Florence and Careggi Hospital were illuminated in the colors of MG to raise awareness of this rare condition.

Let’s continue to shine a light on MG and support research, early diagnosis, and access to care

[Alberto Vogrig @Vogrig_Alberto]

🧠✨ What an incredible 2 days at #AutoimmuneNeurologyUpdate2026 in Alghero! Brilliant speakers from across Europe, cutting-edge science, and the breathtaking Sardinian coast surrounding us! The future of Italian neuroimmunology looks bright! @GruppoNina @EliaSechi @MGastaldi85

[Mayo Florida AutoImmune Neurology Group @Mayo_AING]

Pragmatic. Full of information. Cutting edge. Cool figs!

Honored to lead The Lancet review on Encephalitis. With amazing Sophie B, Ava E, Kiran T & @DeannaSaylor1

We hope you enjoy reading it:
https://t.co/0baEHVhjeH

@mayoneurores @mayocliniclabs @MayoClinic @NDCNOxford

[Eoin Flanagan @EoinFlanagan14]

So exciting to see @mlevy18 present at #AANAM on satralizumab as the 1st proven treatment for attack-prevention in #MOGAD ➡️ A wonderful day for the #MOGAD community!

[Joe Sabatino @jsabatino37]

Excellent new commentary from @ZamvilScott and Larry Steinman on the 3 recent EBV-MS papers in @CellCellPress: https://t.co/TTinywMTv5

[Gregorio Spagni @SpagniGregorio]

@GianvitoMasi @OConnorLabYale @Brain1878 Impressive work. congratulations!

[Gianvito Masi @GianvitoMasi]

@OConnorLabYale and I are thrilled to share that our new study on MuSK myasthenia gravis (MG) has just been published in @Brain1878 !👇 (1/8)
https://t.co/apWFEHs9rT

[Elia Sechi @EliaSechi]

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management by the NINA Group @GruppoNina 🇮🇹 - Journal of Neuroimmunology https://t.co/JpSS8EFLMD

[Elia Sechi @EliaSechi]

Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis | Neurology Neuroimmunology & Neuroinflammation https://t.co/eqj2ot5yEf @PietroZara6 @MGastaldi85 @SaraMariottoMD @RosaCortese5 @CartaSra and Giacomo Greco 🇮🇹💣

[Fabienne Brilot @FabienneBrilot]

Our meta analysis of biomarkers predicting relapse in #MOGAD is out!
https://t.co/dm9nhEF6go
Relapsing course associated with:
➡️persistent MOG-IgG seropositivity
➡️delayed seroreversion

Higher risk of attack associated with:
➡️ higher MOG-IgG titer
➡️CSF leucocytosis
@darshi_r

[French Reference Center for PNS and AE @LyonPNS_AE]

🧠🧩 New clues in autoimmune encephalitis: neuron-reactive KIR+ CD8+ T cells show dysregulated activity, pointing to a driver of disease.
🔗 https://t.co/I5Z2ZtQJTa

[Gregorio Spagni @SpagniGregorio]

@JamesRottger @CorranFerry @HighlandCouncil @trafficscotland @NWTrunkRoads Yes, we are boarding with our car right now direction Corran

[Gregorio Spagni @SpagniGregorio]

@D1ngbat3 @CorranFerry @trafficscotland @HighlandCouncil @NWTrunkRoads It is now operating also for cars

[Gregorio Spagni @SpagniGregorio]

📝Main findings:
1️⃣PASS=YES thresholds:
MG-ADL ≤ 2
QMG ≤ 8
MG-QOL15r ≤ 6

2️⃣PASS captures partially distinct dimensions vs. MGFA-PIS

3️⃣ocular involvement=strongest negative predictor of symptom acceptability (PASS=YES)

Now published in @EurJournalNeuro !

[Gregorio Spagni @SpagniGregorio]

Check out our new paper on the Patient-acceptable symptom state (PASS) question in AChR MG! 🧠

A step forward in aligning clinical metrics with patient perception.

Thanks to all co-authors for the wonderful teamwork @damato_v @neuro_bo @silvia_falso

https://t.co/nbE1WeJbZR

[Journal of Neurology, Neurosurgery and Psychiatry @JNNP_BMJ]

Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks
https://t.co/bUToBLxPsj @NeuroVisionLab

[Elia Sechi @EliaSechi]

Very nice study comparing sensitivity and specificity of live vs fixed CBA for AQP4 and MOG Ab detection in clinical practice. Live CBA offers a big gain in sensitivity and help not miss real cases with the disease! https://t.co/be0ey81zlk @ESotirchos @EoinFlanagan14 @chenmayo

[Matteo Gastaldi @MGastaldi85]

https://t.co/ZJHaeghpzv

Proud to share @StefanoMascio91 latest work on PLP1 antibodies in demyelinating diseases. PLP1 abs are mainly found in patients with non MS diseases with combined central and peripheral demyelination, but also in rare seronegative NMOSD